妇儿健康导刊2025，Vol.4Issue(6)：35-39,44,6.DOI:10.3969/j.issn.2097-115X.2025.06.005
子宫腺肌病的药物治疗进展
Advances in the pharmacologic treatment of adenomyosis
殷照园 1郏柯 1杨菲 1张萍 1赵芳1
作者信息
- 1. 苏州大学附属张家港医院 张家港市第一人民医院妇科,江苏张家港 215600
- 折叠
摘要
Abstract
Adenomyosis is one of the common gynecological diseases among women of childbearing age.In recent years,the incidence rate has been on the rise,with the incidence of the population trending towards a younger age group.The progressively worsening dysmenorrhea,excessive menstrual flow,and infertility caused by this disease have a significant impact on women's physical and mental health and quality of life.The primary objective of treatment is to alleviate the patient's discomfort,regulate bleeding,and enhance fertility through a range of therapeutic approaches.Currently,there are no specific pharmaceuticals for adenomyosis,and no established guidelines for diagnosis and treatment.Pharmacological treatment is the preferred option due to its affordability,effectiveness,rapid symptomatic relief,and preservation of fertility.Non-steroidal anti-inflammatory drugs,oral contraceptives,progestins,and gonadotropin-releasing hormone analogs have been demonstrated to be effective in relieving pain and controlling abnormal uterine bleeding.Among these,the Levonorgestrel-releasing intrauterine system is particularly effective in reducing abnormal uterine bleeding and shrinking uterine size in drug long-term management therapy,and it is therefore expected to become an effective alternative treatment to hysterectomy.In recent years,a number of new drugs have also been under development.However,the specific efficacy of these drugs must be confirmed by high-quality research data due to the lack of relevant clinical trial studies.关键词
子宫腺肌病/左炔诺孕酮宫内缓释系统/药物治疗Key words
Adenomyosis/Levonorgestrel-releasing intrauterine system/Pharmacologic treatment分类
临床医学引用本文复制引用
殷照园,郏柯,杨菲,张萍,赵芳..子宫腺肌病的药物治疗进展[J].妇儿健康导刊,2025,4(6):35-39,44,6.
